Methylcobalamin and adenosylcobalamin are pre-activated forms some practitioners prefer, particularly for individuals with genetic variations affecting B12 metabolism
Eric Topol of Scripps Research Translational Institute was more direct: "These peptides have no data to support their safety and efficacy." The clinical proponents argue that the FDA's safety concerns immunogenicity risk, impurity risk, organ toxicity are theoretically valid but speculative in practice
Until they do, every clinical application of BPC-157 carries a degree of uncertainty that informed patients and physicians must acknowledge explicitly
To learn more or to get involved, email [email protected]
Vasavada A, Patel P, Sanghavi DK
at the Puno station, departing at 7:30 a.m